AstraZeneca PLC (LON:AZN) Rating Reaffirmed
Deutsche Bank has decided to reaffirm their “Buy” rating on AstraZeneca PLC (LON:AZN) in a note made public on 30 November.
From a total of 24 analysts covering AstraZeneca PLC (LON:AZN) stock, 11 rate it a ”Buy”, 4 a “Sell”, and 9 a ”Hold”. This means that 46% of the ratings are positive. The highest target price is GBX 6600 while the lowest target price is GBX 3700. The mean of all analyst targets is GBX 4831.29 with a 6.89% above today’s (GBX 4519.68) stock price. AstraZeneca PLC was the topic of 115 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank maintained shares on November 30 with “Buy” rating. Helvea maintained shares with “Hold” rating and GBX 4400 target share price in a report from a November 23. Goldman Sachs maintained AZN stock in a recent report from November 24 with “Neutral” rating. Jefferies maintained the rating on November 18. Jefferies has a “Buy” rating and a GBX 5600 price target on shares. Finally, Credit Suisse maintained the stock with “Underperform” rating in a report issued on a November 24.
The stock increased 0.16% or GBX 7.18 on November 27, striking GBX 4519.68. Approximately shares of stock traded hands. AstraZeneca plc (LON:AZN) has risen 1.14% since May 1, 2015 and is uptrending. It has outperformed by 2.04% the S&P500.
AstraZeneca PLC is a global biopharmaceutical company. The company has a market cap of 57.03 billion GBP. The Firm discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. It has 50.93 P/E ratio. The Company’s medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants.
According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.” Get a free copy of the Zacks research report on AstraZeneca plc (AZN)